Vista Pharmaceuticals (524711) Q2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 earnings summary
13 Nov, 2025Executive summary
Board approved unaudited financial results for the quarter and half year ended 30 September 2025, along with the limited review report by statutory auditors.
Financial statements prepared in accordance with Indian Accounting Standards (Ind AS).
Financial highlights
Total revenue for Q2 FY26 was ₹165.49 lakhs, down from ₹250.17 lakhs in Q2 FY25.
Loss before tax for Q2 FY26 was ₹362.21 lakhs, compared to a loss of ₹125.20 lakhs in Q2 FY25.
Net loss for Q2 FY26 stood at ₹258.85 lakhs, versus ₹129.04 lakhs in Q1 FY26 and ₹97.37 lakhs in Q2 FY25.
Basic EPS for Q2 FY26 was (₹0.42), compared to (₹0.16) in Q2 FY25.
Outlook and guidance
Management recognized a provision for expected credit loss (ECL) of ₹205.43 lakhs in Q2 FY26, reflecting a cautious outlook on long-pending trade receivables.
Latest events from Vista Pharmaceuticals
- Nil revenue, continued losses, and NPA status raise significant going concern risks.524711
Q1 26/27 - Audited FY26 results received an unqualified opinion; new internal auditor appointed for FY27.524711Q4 25/26
- Q3 FY26 saw higher net loss and ECL provision, with statutory dues outstanding.524711Q3 25/26
- Revenue fell and losses deepened in Q1 FY26, with leadership continuity affirmed.524711Q1 25/26
- Q2 FY25 saw lower revenue but reduced losses and stronger equity from capital raising.524711Q2 24/25
- Q1 FY25 saw lower revenue and a net loss, with AGM scheduled for September 30, 2024.524711Q1 24/25
- Net loss persists despite revenue growth; WHO certification and audit opinion boost credibility.524711Q4 24/25
- Q3 FY25 revenue surged, but losses continued; WHO certification marks a key milestone.524711Q3 24/25